

FINAL
DRAFT

INTERNATIONAL
STANDARD

ISO/FDIS
23217

ISO/TC 84

Secretariat: DS

Voting begins on:
2023-11-15

Voting terminates on:
2024-01-10

Injection systems for self- administration by paediatric patients — Requirements and guidelines for design

*Systèmes d'injection pour auto-administration par des patients
pédiatriques — Exigences et lignes directrices relatives à la
conception*

iteh standards
(<https://standards.iteh.ai>)
Document Preview

ISO/FDIS 23217

<https://standards.iteh.ai/catalog/standards/sist/9fb474a4-f5c6-4d0b-a170-16229e37c797/iso-fdis-23217>

RECIPIENTS OF THIS DRAFT ARE INVITED TO SUBMIT, WITH THEIR COMMENTS, NOTIFICATION OF ANY RELEVANT PATENT RIGHTS OF WHICH THEY ARE AWARE AND TO PROVIDE SUPPORTING DOCUMENTATION.

IN ADDITION TO THEIR EVALUATION AS BEING ACCEPTABLE FOR INDUSTRIAL, TECHNOLOGICAL, COMMERCIAL AND USER PURPOSES, DRAFT INTERNATIONAL STANDARDS MAY ON OCCASION HAVE TO BE CONSIDERED IN THE LIGHT OF THEIR POTENTIAL TO BECOME STANDARDS TO WHICH REFERENCE MAY BE MADE IN NATIONAL REGULATIONS.



Reference number
ISO/FDIS 23217:2023(E)

© ISO 2023

iTeh Standards
(<https://standards.iteh.ai>)
Document Preview

[ISO/FDIS 23217](https://standards.iteh.ai/catalog/standards/sist/9fb474a4-f5c6-4d0b-a170-16229e37c797/iso-fdis-23217)

<https://standards.iteh.ai/catalog/standards/sist/9fb474a4-f5c6-4d0b-a170-16229e37c797/iso-fdis-23217>



COPYRIGHT PROTECTED DOCUMENT

© ISO 2023

All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
CP 401 • Ch. de Blandonnet 8
CH-1214 Vernier, Geneva
Phone: +41 22 749 01 11
Email: copyright@iso.org
Website: www.iso.org

Published in Switzerland

Contents

| | Page |
|--|-----------|
| Foreword | iv |
| Introduction | v |
| 1 Scope | 1 |
| 2 Normative references | 1 |
| 3 Terms and definitions | 1 |
| 4 Considerations for design inputs | 5 |
| 4.1 General..... | 5 |
| 4.2 Risk assessment and usability engineering..... | 5 |
| 4.2.1 Risk assessment..... | 5 |
| 4.2.2 Usability engineering..... | 5 |
| 4.3 Considerations for the determination of requirements for the design of medical devices specific to paediatric users..... | 5 |
| 4.3.1 Considerations in relation to risk (risk-based approach to design)..... | 5 |
| 4.3.2 Considerations in relation to human factors..... | 5 |
| 4.3.3 Considerations for accompanying documentation..... | 12 |
| 5 Development of the design | 12 |
| 6 Design verification and validation | 13 |
| 6.1 General..... | 13 |
| 6.2 Design verification..... | 13 |
| 6.3 Design validation..... | 13 |
| 6.3.1 General..... | 13 |
| 6.3.2 Usability evaluations (also known as usability tests or user studies)..... | 13 |
| 6.3.3 Clinical evaluation..... | 14 |
| Annex A (informative) Additional considerations for the “paediatric population” | 16 |
| Bibliography | 38 |

[ISO/FDIS 23217](https://standards.iteh.ai/catalog/standards/sist/9fb474a4-f5c6-4d0b-a170-16229e37c797/iso-fdis-23217)

<https://standards.iteh.ai/catalog/standards/sist/9fb474a4-f5c6-4d0b-a170-16229e37c797/iso-fdis-23217>

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

ISO draws attention to the possibility that the implementation of this document may involve the use of (a) patent(s). ISO takes no position concerning the evidence, validity or applicability of any claimed patent rights in respect thereof. As of the date of publication of this document, ISO had not received notice of (a) patent(s) which may be required to implement this document. However, implementers are cautioned that this may not represent the latest information, which may be obtained from the patent database available at www.iso.org/patents. ISO shall not be held responsible for identifying any or all such patent rights.

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT), see www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 84, *Devices for administration of medicinal products and catheters*.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

Introduction

An increasing number of therapies for paediatric use rely upon a drug delivery system for administration. However, many existing drug delivery systems in widespread use incorporate design features that might not conform with current thinking on human factors/usability engineering principles for use by the paediatric population or include some significant differences from those applicable to the average adult user population and other demographic groups. In some cases, these design features can result in incorrect use of the drug delivery system and unacceptable risks.

Therefore, guidelines on the design input to the development of drug delivery systems specifically intended for administration of medicinal products by paediatric users are relevant. Especially, guidelines are relevant for development of those devices where the paediatric user is performing some or all use steps. The guidelines in this document are dedicated to those products. Guidelines in relation to the development of products intended for administration of medicinal products by caregivers only are not covered by this document as those devices are developed for the average adult population.

Due to the variation of design of drug delivery systems, this document does not specify requirements for developing, assessing and evaluating drug delivery systems.

Manufacturers should follow a risk-based approach during the design and development of drug delivery systems serving the paediatric population.

[Figure 1](#) summarizes the applicability of this document.




Figure 1 — Roadmap for the use of this document

Guidance on transition periods for implementing the content of this document is given in ISO/TR 19244.

Injection systems for self-administration by paediatric patients — Requirements and guidelines for design

1 Scope

This document provides requirements and guidelines on the development of drug delivery systems intended for self-administration of medicinal products by the specific demographic group of paediatric patients who are performing some or all use steps required for their intended use.

Use steps include any handling action performed after the patient has received the product; these can include but are not limited to:

- transport – carrying the product while travelling (e.g. by walking, train, airplane, automobile, bus);
- storage – storage by the patient in their home, school, office or in temporary storage cases before or between uses;
- preparation – steps necessary to place the product in a state where it is ready to be administered;
- operation – steps necessary to initiate, adjust, pause, stop, or otherwise manage the delivery of medication using the product;
- maintenance – steps necessary to keep the product in good working order;
- disposal – steps to ensure safe disposal of the product after use (e.g. placement of the product in a suitable receptacle).

This document is applicable to injectable drug delivery systems for administration of medicinal products. Furthermore, this document can be useful for the development of other drug delivery devices or systems if they are intended for use by the paediatric population. Devices not in the scope of this document include catheters, for example those in the scope of ISO 10555 series, and infusion pump systems, e.g. IEC 60601-2-24 and aerosol delivery devices (ISO 20072).

2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 13485, *Medical devices — Quality management systems — Requirements for regulatory purposes*

ISO 14971:2019, *Medical devices — Application of risk management to medical devices*

IEC 62366-1, *Medical devices — Part 1: Application of usability engineering to medical devices*

3 Terms and definitions

For the purposes of this document, the following terms and definitions apply.

ISO and IEC maintain terminology databases for use in standardization at the following addresses:

- ISO Online browsing platform: available at <https://www.iso.org/obp>
- IEC Electropedia: available at <https://www.electropedia.org/>

**3.1
accompanying documentation**

materials accompanying a medical device and containing information for the *user* (3.15) or those accountable for the installation, use and maintenance of the medical device, particularly regarding safe use

Note 1 to entry: The accompanying documentation can consist of the *instructions for use* (3.8), technical description, installation manual, quick reference guide, etc.

Note 2 to entry: Accompanying documentation is not necessarily a written or printed document but can involve auditory, visual, or tactile materials and multiple media types.

Note 3 to entry: Medical devices that can be used safely without instructions for use are exempted from having instructions for use by some authorities with jurisdiction.

[SOURCE: ISO 14971:2019, 3.1, modified — "decommissioning and disposal" have been deleted from the definition, and Note 3 to entry has been added.]

**3.2
caregiver**

non-professionals (e.g. family members, parents, guardians or friends) who provide care to the *patient* (3.11)

**3.3
drug delivery system**

medical device or system whose primary purpose is the administration of a medicinal product such as drugs and biologics

Note 1 to entry: This term applies to combination of components and subassemblies of the system that are intended to be integrated with the medicinal product with the purpose of providing a method of administration of the medicinal product.

[SOURCE: ISO 20069:2019, 3.1.2]

**3.4
harm**

injury or damage to the health of people, or damage to property or the environment

**3.5
hazard**

potential source of *harm* (3.4)

[SOURCE: ISO/IEC Guide 63:2019, 3.2]

**3.6
health care provider**

healthcare professional with proficient skills and experience with the use of a device so that they can aid or train patients and *caregivers* (3.2) to use and maintain the device

**3.7
usability engineering
human factors engineering
UE/HFE**

application of knowledge about human behaviour, abilities, limitations, and other characteristics to the design of medical devices (including software), systems and tasks to achieve adequate *usability* (3.13)

Note 1 to entry: Achieving adequate usability can result in acceptable *risk* (3.19) related to use.

[SOURCE: IEC 62366-1:2015, 3.17]

3.8 instructions for use IFU

directions provided by the manufacturer for the correct handling and operation of the *drug delivery system* (3.3)

[SOURCE: ISO 11608-1:2022, 3.10, modified — “needle-based injection system” replaced with “drug delivery system”.]

3.9 intended use use specification intended purpose

use for which a product, process or service is intended according to the specifications, instructions and information provided by the manufacturer

Note 1 to entry: The intended medical indication, patient population, part of the body or type of tissue interacted with, *user profile* (3.17), use environment, and operating principle are typical elements of the intended use.

[SOURCE: ISO/IEC Guide 63:2019, 3.4, modified — the preferred terms “use specification” and “intended purpose” have been added.]

3.10 paediatric

relating to children and/or adolescents

Note 1 to entry: The definition of paediatric varies by region and organization. See [Annex A](#) for different organizations’ classifications of “child” and “adolescent”.

3.11 patient

person undergoing a medical, surgical, or dental procedure

3.12 self-administration

process by which the *patient* (3.11) enters medication into their own body

3.13 usability

characteristic of the *user interface* (3.16) that facilitates use and thereby establishes effectiveness, efficiency and user satisfaction in the intended use environment

Note 1 to entry: All aspects of usability, including effectiveness, efficiency, and user satisfaction, can either increase or decrease safety.

[SOURCE: IEC 62366-1:2015, 3.16]

3.14 use error

user (3.15) action or lack of user action while using the medical device that leads to a different result than intended by the manufacturer or expected by the user

Note 1 to entry: Use error includes the inability of the user to complete a task.

Note 2 to entry: Use errors can result from a mismatch between the characteristics of the user, *user interface* (3.16), task, or use environment.

Note 3 to entry: Users can be aware or unaware that a use error has occurred.

Note 4 to entry: An unexpected physiological response of the *patient* (3.11) is not by itself considered use error.

Note 5 to entry: A malfunction of a medical device that causes an unexpected result is not considered a use error.

[SOURCE: IEC 62366-1:2015, 3.21, modified — Note 6 to entry has been deleted.]

3.15

user

person interacting with (i.e. operating or handling) the medical device

Note 1 to entry: There can be more than one user of a medical device.

Note 2 to entry: Common users include clinicians, *health care providers* (3.6), *patients* (3.11), *caregivers* (3.2).

[SOURCE: IEC 62366-1:2015, 3.24, modified — Note 2 to entry has been changed.]

3.16

user interface

means by which the *user* (3.15) and the medical device interact

Note 1 to entry: User interface includes all the elements of the medical device with which the user interacts including *accompanying documentation* (3.1), packaging, and the physical aspects of the medical device as well as visual, auditory, tactile displays and is not limited to a software interface.

Note 2 to entry: A system of medical devices can be treated as a single user interface.

[SOURCE: IEC 62366-1:2015, 3.26, modified — Note 1 to entry has been deleted.]

3.17

user profile

summary of the mental, physical and demographic traits of a *user* (3.15) group, as well as characteristics, such as knowledge, skills and abilities, which can have a bearing on design decisions

[SOURCE: IEC 62366-1:2015/Amd 1:2020, 3.29]

3.18

residual risk

risk (3.19) remaining after *risk control* (3.21) measures have been implemented

[SOURCE: ISO/IEC Guide 63:2019, 3.9]

ISO/FDIS 23217

<https://standards.iteh.ai/catalog/standards/sist/9fb474a4-f5c6-4d0b-a170-16229e37c797/iso-fdis-23217>

3.19

risk

combination of the probability of occurrence of *harm* (3.4) and the severity of that harm

[SOURCE: ISO/IEC Guide 63:2019, 3.10, modified — Note 1 to entry deleted.]

3.20

risk analysis

systematic use of available information to identify *hazards* (3.5) and to estimate the *risk* (3.19)

[SOURCE: ISO/IEC Guide 63:2019, 3.11]

3.21

risk control

process in which decisions are made and measures implemented by which *risks* (3.19) are reduced to, or maintained within, specified levels

[SOURCE: ISO/IEC Guide 63:2019, 3.12]

3.22

risk evaluation

process of comparing the estimated *risk* (3.19) against given risk criteria to determine the acceptability of the risk

[SOURCE: ISO/IEC Guide 63:2019, 3.14]

4 Considerations for design inputs

4.1 General

The specific requirements that shall be fulfilled for a specific demographic population can partly be developed by applying the risk approach (see 4.2.1) and usability engineering (see 4.2.2) specified in applicable standards.

4.2 Risk assessment and usability engineering

4.2.1 Risk assessment

The manufacturer shall perform risk analysis, risk evaluation, risk control and an evaluation of residual risk acceptability in accordance with ISO 14971.

4.2.2 Usability engineering

A usability engineering program in accordance with IEC 62366-1 shall be applied. It shall include addressing use risks and tests and/or assessments throughout the development and as part of the design verification and design validation.

4.3 Considerations for the determination of requirements for the design of medical devices specific to paediatric users

4.3.1 Considerations in relation to risk (risk-based approach to design)

The risk assessment in accordance with ISO 14971 shall take into account the characteristics of the paediatric users including use risks in accordance with IEC 62366-1. See [Table A.4](#) for examples of potential use errors.

4.3.2 Considerations in relation to human factors

<https://standards.iteh.ai/catalog/standards/sist/9fb474a4-f5c6-4d0b-a170-16229e37c797/iso-fdis-23217>

4.3.2.1 General

During the design and development of a drug delivery system intended for self-administration by paediatric users, the intended uses, intended user profiles, and use environments shall be identified and clearly defined.

Based on the human factors' considerations, the requirements for the medical device shall be documented.

NOTE [Subclause 4.3.2](#) is intended to highlight aspects of the HFE/UE process defined and documented in IEC 62366-1 that require special attention when developing drug delivery systems for paediatric use.

4.3.2.2 Characterization of the intended use

4.3.2.2.1 Intended user profiles

The socio-economic environment, cognitive and physical development, age and aptitude of the intended user shall be defined. Within the population of paediatric users, variation can be expected in terms of size, strength, stamina, skeletal maturity, coordination (e.g. gross and fine motor skills), visual, tactile, auditory and perceptual capabilities, emotional maturity, motivation, decision-making abilities and the impact of their medical condition on their ability to use the drug delivery system safely and effectively. Furthermore, if it is anticipated that a paediatric user needs the support of a healthcare provider or caregiver to use the drug delivery system, the limitations and capabilities of adult users shall also be defined.

4.3.2.2.2 Intended use environment

The environment of intended use shall be characterized. Paediatric users tend to lead active lifestyles and so some medical products are used outside of the home (e.g. at school or on sports fields). During these use scenarios they can be exposed to environmental factors (e.g. bright sunlight or excess temperatures) or used in a non-private setting.

4.3.2.3 Use-related risk

Manufacturers shall identify hazard-related use scenarios in accordance with IEC 62366-1, including potential use errors that can occur, identify known or foreseeable hazards and hazardous situations, and ensure that they are adequately controlled. When identifying and evaluating use-related risk, the content of the intended use shall be defined, and for drug delivery systems that are similar to the one under development with regard to use, the user interface or user interactions shall be analysed. The source of identification of potential use errors and risks can include human factors evaluations, literature research, and market experience.

4.3.2.4 User interface

4.3.2.4.1 General

When developing user interface requirements, the following aspects shall be evaluated.

It shall be evaluated how risks can be suitably controlled through the design of the drug delivery system including its associated materials. As covered in ISO 14971:2019, 6.2 the manufacturer shall use one or more of the following risk control options in the priority order listed:

- a) inherent safety by design;
- b) protective measures in the medical device itself or in the manufacturing process;
- c) information for safety.

4.3.2.4.2 Design attributes

The characteristics of the paediatric user shall inform the design and development of a drug delivery system.

General drug delivery system design considerations are given in [Table 1](#).

4.3.2.4.3 Training

While it is preferable to control risks through drug delivery system design, including associated materials, in some circumstances, mitigation by design alone can be insufficient for a paediatric population. In these situations, it can be appropriate to employ a training program. If training is a necessary component to mitigate risk of the drug delivery system, the manufacturer shall validate the effectiveness of the training program and justify how it is representative of the training that will be provided in commercial use of the drug delivery system.

The manner in which the training will be consistently implemented in the field shall be defined, however the risk of users not being trained shall also be assessed. For example, lay caregivers can learn how to use the system by observing a patient or another lay caregiver, and health care providers might not be directly trained.

4.3.2.4.4 Experience and knowledge of similar or other drug delivery systems

Paediatric users vary in their experience of managing their medication and of using similar drug delivery systems. Similarly, the knowledge and experience of their supporting health care provider or